WuXi AppTec climbed 5.1%, while travel platform Trip.com advanced 4.7%. China’s CSI 300 Index rose 0.9%, and the Shanghai Composite ... simple by copying our team of pro-traders.

WuXi AppTec Co, Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene ...

WuXi AppTec is parting ways with its U.S. medical ... to growing the operations in ways that will benefit their talented team members but also to serving our life science customers and enabling ...

WuXi AppTec’s leadership played down concerns about reduced demand for glucagon-like peptide-1 receptor agonist (GLP-1RA) manufacturing after leading obesity player Eli Lilly released lower-than ...

Contract research organisation (CRO) NAMSA has acquired the US-based medical device testing operations of WuXi AppTec to strengthen its medtech clinical research testing capabilities. The deal ...

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from ...

Chinese contract drug maker WuXi AppTec rose 7.0% in afternoon trade in Hong Kong, on track for its largest daily percentage gain since early December. Its sister company WuXi Biologics rose 4.7% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...